Pliant Therapeutics, Inc.PLRXNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Gross Profit Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +1.06% | +1.73% | +1.66% | +1.11% | +1.37% |
| Weighted Average Shares Diluted Growth | +1.06% | +1.73% | +1.66% | +1.11% | +1.37% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | -23.19% | -27.30% | -45.24% | -59.04% | -64.25% |
| Inventory Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Asset Growth | -22.49% | -33.90% | -38.02% | -37.94% | -43.26% |
| Book Value per Share Growth | -36.46% | -42.20% | -44.87% | -42.72% | -41.21% |
| Debt Growth | +429.30% | +10.10% | +0.25% | -0.59% | -51.65% |
| R&D Expense Growth | +16.91% | +18.57% | -28.44% | -62.44% | -59.83% |
| SG&A Expenses Growth | +4.86% | +1.66% | -10.84% | -27.55% | -44.99% |